glp-1 demand Agonists Weight Loss Drugs Market Report, 2025-2030 GLP-1 Receptor Agonist Market Size

J Endocrinol Invest 39: 1323-1327

The best quality evidence is that which demonstrates significant positive outcomes, on human subjects, in multiple, double-blinded controlled studies

These unstable intermediate complexes can undergo further chemical transformations into toxic dopamine-derived species, and such dopamine-quinone derivatives are well-documented to impair mitochondrial function and exert direct neurotoxic effects on SN dopaminergic neurons, contributing to their selective vulnerability in pathological states like PD (126)

"Ipamorelin, the first selective growth hormone secretagogue." European journal of endocrinology 139.5 (1998): 552-561

[DOI] [Google Scholar] 62.Koc M., Imik H., Odabasoglu F